Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice-a-day Pylera or L. reuteri for H. pylori
NCT03925818Terminated
- Sponsor
- University of Sassari
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of bismuth subcitrate potassium + metronidazole + tetracycline hydrochloride in Helicobacter pylori infection (2 arms), sponsored by University of Sassari. Primary endpoint: Helicobacter pylori eradication rate. Started Aug 2017; status: terminated.
02
Drugs
bismuth subcitrate potassium + metronidazole + tetracycline hydrochloride
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03925818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925818.